Vol. 35 No. 6 Jun Infectious Agents Surveil http://www.nih.go.jp/niid/en/	lance Report Control Division.			
Clinical virology of RSV139	An imported case of chikungunya fever from the Kingdom of Tonga,			
Recent developments for RSV research in children	March 2014–Mie Prefecture 152			
Variability in clinical outcomes of RSV infection142	An outbreak of psittacosis in a social welfare facility, February 2014			
Development of a web-based surveillance system for RSV	–Kawasaki City153			
infection	Recent increase of hepatitis A infection in Japan, 2014: caution			
An outbreak of infectious respiratory illness caused by RSV at an	against false negative results based on the recommended			
institution for children with developmental disabilities,	real-time PCR protocol154			
August 2011–Okinawa Prefecture	Selection of antibiotics for screening carbapenem-resistant			
RSV outbreak at a nursing home for the elderly, January 2014–	Enterobacteriaceae156			
Ibaraki Prefecture146	Notice from MHLW: Decision on influenza virus strains to be used			
RSV infection: an important illness among the elderly and adult 147	for influenza HA vaccine in Japan, 2014/15 season			
Molecular epidemiology of RSV in Japan	An outbreak of respiratory infections associated with several			
RSV epidemiology in the Philippines and its implications	parainfluenza viruses (type 3 & 4b), October-November 2013			
Report of two falciparum malaria cases, including an adult case of	-Chiba City			
cerebral malaria complication, among a group of travelers to	A case of botulism due to <i>Clostridium butyricum</i> , February 2014			
Kenya, March 2014 151	–Miyazaki Prefecture159			

## <THE TOPIC OF THIS MONTH> Respiratory syncytial virus infection, as of May 2014

Respiratory syncytial virus (RSV) is an RNA virus belonging to Pneumovirus in Paramyxoviridae family (see p. 148 of this issue). It is propagated as droplet or contact infections. Estimatedly, more than 50% of infants acquire primary infection during the first year of life and nearly 100% before their second birthday. No first infection confers lifelong immunity (see p. 141 of this issue).


RSV infection occupies 50% of pneumonia and 50-90% of bronchiolitis among infants (see p. 139 & 142 of this issue). The clinical manifestation is indistinguishable from other respiratory virus infections. Therefore, laboratory diagnosis is indispensable for differential diagnosis. Clinical treatment of the patients is basically supportive.

Newborn, infant and immunocompromised cases tend to become serious (see pp. 139 & 150 of this issue) with development of apnea, syndrome of inappropriate antidiuretic hormone (SIADH), acute encephalopathy and other complications. Adult cases are


generally mild (with flu-like symptoms) though they may transmit RSV to others. Aged cases may develop pneumonia as severe as that associated with influenza, and their case fatality rate is high (see p. 147 of this issue). Preventive measures against nosocomial RSV infection including early diagnosis should be implemented in facilities for elderlies or persons with disabilities, as RSV outbreaks have been reported from such facilities (see pp. 145 & 146 of this issue).


Currently, no preventive vaccines against RSV infection are available, though a humanized monoclonal antibody to RSV F glycoprotein, palivizumab, (developed in the USA and commercially available in Japan since 2002) is administered to high risk groups, such as, premature babies, patients with chronic pulmonary or congenital heart disease(s) for preventing RSV infection.

RSV infection is a category V infectious disease under the Infectious Diseases Control Law since its amendment in 2003. In compliance with the Law and under the framework of the National Epidemiological Surveillance of Infectious Diseases (NESID), pediatric sentinels report the notified RSV cases every week to the local public health centers. Notification requires laboratory diagnosis in-









<sup>\*</sup> Patients whose RSV antigen tests are covered by the medical insurance

(3) All the hospitalized patients and the outpatients who are infants and/or patients to whom palivizumab is indicated: since 17 October 2011

① Hospitalized patients less than 3 years of age: since 2003 ② All the hospitalized patients: since April 2006

## (THE TOPIC OF THIS MONTH-Continued)

Figure 3. Weekly cases of RSV infection by region, week 1 of 2008-week 16 of 2014, Japan

 $(National \ Epidemiological \ Surveillance \ of \ Infectious \ Diseases: \ as \ of \ April \ 23, \ 2014)$ 




Table 1. Acute encephalopathy cases due to								
respiratory syncytial virus, Japan.	2008-2013							

	respiratory sy	neymai vii u	is, oupuii,	, 2000 201
Year	Month of	Age	Gender	Remarks
	diagnosis	(years)	Genuer	Remarks
2008	December	2	Female	
	March	2	Male	Dead
2009	December	2	Male	
	December	2	Male	
	January	1	Male	
	February	2	Male	
2010	February	1	Male	
	September	1	Female	
	September	13	Female	
	February	5	Male	
	April	3	Female	
2011	June	1	Female	
	July	11	Female	
	December	2	Female	
	January	2	Male	
2012	April	0 (8 mo.)	Female	Dead
2012	July	0 (5 mo.)	Female	
	November	2	Male	
	September	0 (11 mo.)	Female	
2013	November	6	Male	
2015	December	1	Female	
	December	0 (10 mo.)	Female	

(National Epidemiological Surveillance of Infectious Diseases: as of April 24 2014)

cluding RSV antigen detection (notification criteria in http:// www.nih.go.jp/niid/images/iasr/35/412/de4121.pdf). Though it had been limited to hospitalized patients before 17 October 2011, the medical insurance now covers RSV antigen detection testing of infants and other outpatients, to whom palivizumab is indicated (see p. 143 of this issue). Among approximately 3,000 pediatric sentinels (hospitals and clinics), now about 80% of them report RSV infection. In particular, clinics without beds increasingly report RSV infection cases in recent years, and the number of RSV infection reporting from such

clinics doubled from 2008 to 2012 (Fig. 1).

**RSV infections under NESID**: During 2012-2013, the RSV infection epidemic started in July; the patients increased rapidly in September; the epidemic reached the peak towards the end of the year; and it continued till spring (Fig. 2). Osaka Prefecture continuously reported the highest number of patients (IASR 29: 271-273, 2008), followed by Hokkaido, Tokyo, Aichi and Fukuoka prefectures; they are all prefectures with high annual number of births. The epidemic season started earlier in Kyushu region. Okinawa Prefecture, differently from other regions, had the epidemic peak in summer (Fig. 3). From 2012 to 2013, there were 105,174 male patients (54%) and 89,370 female patients (46%). Infants under 2 years of age occupied 90% of the patients; the frequency proportion among <2 year patients was in the order of 0 year, 1 year and 2 years (Fig. 4 in p. 139 of this issue).

Since 2008, 22 RSV-related acute encephalopathy cases including 2 fatal cases (10 males, 12 females; 17 patients less than 2 years of age) have been reported. The patients' age ranged from 5 months to 13 years (median 2 years), which corresponds to the age groups whose RSV infection tends to be serious (Table 1).

**Detection of RSV and other respiratory infectious viruses**: Prefectural and municipal public health institutes (PHIs) isolate/detect virus from specimens sent from pathogen sentinels [corresponding about 10% of influenza sentinels (3,000 pediatric and 2,000 internal medicine clinics) and 500 sentinel hospitals]. Until 2009/10 influenza season, RSV was the second highest in detection frequencies following influenza, but since 2010/11 season, rhinovirus detections exceeded RSV detections (Table 2 in p. 139 of this issue). RSV was isolated/detected from autumn to winter; influenza in winter; and rhinovirus throughout the year (Fig. 5 in p. 139 of this issue). Human metapneumovirus and parainfluenza viruses (see p. 157 of this issue), though small in number, were isolated/detected most frequently from spring to summer.

In 2008/09-2013/14 season, 57 PHIs in 44 prefectures isolated/detected RSV from 5,441 cases (as of 20 May 2014). The most frequent RSV-positive specimens were throat swab (5,358 specimens, 98%) and the most frequent detection method applied was PCR (4,959 cases, 91%) followed by cell culture isolation (932 cases, 17%), and antigen detection (49 cases, 1%) (detection by more than one method included). The most frequent respiratory disease-related diagnosis of the cases from which the specimens were collected was lower respiratory tract inflammation (2,371 cases, 44%) followed by RSV infection (1,746 cases, 32%) and upper respiratory tract inflammation (495 cases, 9%).

**Challenges in future**: RSV infection is associated with high incidence of pneumonia among aged groups and serious complications among infants. To reduce the disease burden, the RSV surveillance system should be strengthened to make evidence based intervention possible.

Infectious Disease Surveillance Center, National Institute of Infectious Diseases Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, JAPAN Tel (+81-3)5285-1111

The statistics in this report are based on 1) the data concerning patients and laboratory findings obtained by the National Epidemiological Surveillance of Infectious Diseases undertaken in compliance with the Law Concerning the Prevention of Infectious Diseases and Medical Care for Patients of Infections, and 2) other data covering various aspects of infectious diseases. The prefectural and municipal health centers and public health institutes (PHIs), the Department of Food Safety, the Ministry of Health, Labour and Welfare, and quarantine stations, have provided the above data.

(特集つづき)

図4. RSウイルス感染症患者の年齢分布, 2008~2013年(感染症発生動向調査: 2014年4月25日現在報告数) Figure 4. Age distribution of RSV infection cases, 2008-2013, Japan

在	(National Epidemiological Surveillance of Infectious Diseases: as of April 25, 2014)									患者報告数	
Year 0%	10	20	30	40	50	60	70	80	90	100	No. of cases
2008		////)								1	53,252
2009 🌌		1									35,012
2010				(							79,094
2011											70,876
2012											98,010
2013	0-5 M(月)  ///		6-11 M		1	Y(歳)		2Y	3Y  4	Y //	96,534
*	2011年10月	RSウイル	レス抗原検査	室の保険運	通用対象が	拡大			5	-9Y  `≥	≥20Y
*	Since Octobe	er 2011, t	he RSV an	tigen tes	t was cove	red by the	medical in	nsurance	·. ·	10-19	Y

 $\ast$  Since October 2011, the RSV antigen test was covered by the medical insurance.

表2. 検体採取シーズン別呼吸器系ウイルス検出状況, 20	007/08~2013/14シーズン
Table 2. Respiratory viruses during 2007/08-2013/14 se	easons

検出ウイルス Virus	検体採取シーズン* Sampling season*								
·····································	2007/08	2008/09	2009/10	2010/11	2011/12	2012/13	2013/14	Total	
Respiratory syncytial virus	412	535	974	939	975	1,164	854	5,853	
Rhinovirus	226	238	645	1,282	1,670	1,581	991	6,633	
Parainfluenza virus	204	338	521	580	729	764	278	3,414	
Parainfluenza virus not typed	2	13	4	1	36	8	1	65	
Parainfluenza virus 1	43	62	129	121	230	222	113	920	
Parainfluenza virus 2	17	55	102	62	69	100	100	505	
Parainfluenza virus 3	141	207	276	381	318	397	39	1,759	
Parainfluenza virus 4	1	1	10	15	76	37	25	165	
Human metapneumovirus	266	244	467	547	545	547	215	2,831	
Human bocavirus	35	40	68	206	233	162	61	805	
Coronavirus	1	-	16	96	61	118	127	419	
Influenza virus A H unknown	-	8	12	2	14	15	4	55	
Influenza virus A H1pdm09	n/a	9,866	22,130	6,257	15	163	3,305	41,736	
Influenza virus A H1	3,819	3,607	-	-	-	-	-	7,426	
Influenza virus A H3	544	2,663	157	3,862	5,143	5,046	1,620	19,035	
Influenza virus B	330	2,039	194	1,848	2,043	1,465	2,592	10,511	
Influenza virus C	24	9	52	12	61	2	9	169	
合 計 Total	5,861	19,587	25,236	15,631	11,489	11,027	10,056	98,887	

\*インフルエンザシーズンによる(各年9月~翌年8月) (病原微生物検出情報:2014年5月20日現在報告数) \* Sampling season is adjusted to that of influenza virus, which is from September to August of the next year. n/a: not applicable 該当なし

(Infectious Agents Surveillance Report: as of May 20, 2014)

## 図5. 検体採取月別呼吸器系ウイルス (RSウイルス, インフルエンザウイルス, ライノウイルス) 検出状況, 2008/09~2013/14シーズン(病原微生物検出情報:2014年5月1日現在報告数)

